Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × Drug Therapy × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 31 Neoplasms 25 Colorectal Neoplasms 18 Ovarian Neoplasms 14 Breast Neoplasms 14 Neoplasm Metastasis 12 Pancreatic Neoplasms 10 Lung Neoplasms 10 Stomach Neoplasms 9 Melanoma 8 Leukemia, Myeloid, Acute 8 Lymphoma, Non-Hodgkin 7 Small Cell Lung Carcinoma 6 Recurrence 6 Liver Neoplasms 5 Leukemia 5 Head and Neck Neoplasms 5 Fallopian Tube Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Lymphoma 4 Gastrointestinal Neoplasms 4 Cholangiocarcinoma 4 Adenocarcinoma 4 Urinary Bladder Neoplasms 3 Triple Negative Breast Neoplasms 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Precision Cell Immunotherapy 3 Neoplasms by Site 3

Interventions

Injections 11 pembrolizumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Nivolumab 6 Cisplatin 5 Capecitabine 5 toripalimab 4 atezolizumab 4 Ipilimumab 4 Gemcitabine 4 tislelizumab 3 Rifampin 3 Itraconazole 3 Carboplatin 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 sintilimab 2 pertuzumab 2 ontuxizumab 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2 Oxaliplatin 2 Midazolam 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡